(NASDAQ: STOK) Stoke Therapeutics's forecast annual revenue growth rate of 70.27% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 32.77%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.78%.
Stoke Therapeutics's revenue in 2026 is $27,588,000.On average, 16 Wall Street analysts forecast STOK's revenue for 2026 to be $2,110,201,692, with the lowest STOK revenue forecast at $1,252,067,200, and the highest STOK revenue forecast at $3,428,279,237. On average, 16 Wall Street analysts forecast STOK's revenue for 2027 to be $3,437,119,333, with the lowest STOK revenue forecast at $626,033,600, and the highest STOK revenue forecast at $7,114,018,181.
In 2028, STOK is forecast to generate $9,707,327,846 in revenue, with the lowest revenue forecast at $5,172,681,664 and the highest revenue forecast at $15,646,323,160.